Pam K. Mangat

Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Ajjai Alva, Pam K. Mangat, Elizabeth Garrett‐Mayer et al. · Journal of Clinical Oncology · 2021 · 182 citations

Medicine, Oncology, Pharmacology +17

Rationale and Design of the Targeted Agent and Profiling Utilization Registry Study

Pam K. Mangat, Susan Halabi, Suanna S. Bruinooge et al. · JCO Precision Oncology · 2018 · 180 citations · Full text

Medicine, Oncology, Pharmacology +17

Palbociclib in Patients With Pancreatic and Biliary Cancer With<i>CDKN2A</i>Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study

Tareq Al Baghdadi, Susan Halabi, Elizabeth Garrett‐Mayer et al. · JCO Precision Oncology · 2019 · 93 citations

Medicine, Oncology, Pharmacology +17

Palbociclib in Patients With Non–Small-Cell Lung Cancer With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study

Eugene R. Ahn, Pam K. Mangat, Elizabeth Garrett‐Mayer et al. · JCO Precision Oncology · 2020 · 69 citations

Medicine, Oncology, Pharmacology +16

Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With<i>ERBB2</i>Amplification or<i>ERBB2/3</i>Mutations: Results From the TAPUR Study

R. Gupta, Funda Meric‐Bernstam, Michael Rothe et al. · JCO Precision Oncology · 2022 · 61 citations

Medicine, Oncology, Pharmacology +17